Click Therapeutics, Inc.

Along with Otsuka Precision Health, Inc. (OPH), Click Therapeutics is proud to announce the launch of Rejoyn™, the first and only FDA-authorized prescription digital therapeutic (PDT) for the adjunctive treatment of Major Depressive Disorder symptoms in adults 22 years and older on an antidepressant medication. This first-of-its-kind digital treatment, which is designed to enhance cognitive control of emotion and reduce depression symptoms, is now available in mobile app stores and can be unlocked with a prescription from a healthcare provider. To learn more about Rejoyn, go to www.rejoyn.com. Healthcare providers can visit www.rejoynhcp.com. #Rejoyn #DigitalTherapeutics #MentalHealthAwareness #PrescriptionDigitalTherapeutics

Randall Stanicky, Chief Financial Officer of Click Therapeutics recently shared his insights on the impact of the Prescription Drug Use Related Software (PDURS) draft guidance on the digitization of pharma pipelines with Partnering for BetterHealth Weekly Newsletter. Randall, as a contributing editor, explains how this draft guidance is paving the way for personalized PDTs, enabling increased partnerships with pharmaceutical manufacturers and spurring digital health innovations that can bridge gaps in treatment to benefit patients. Read more about the future of drug-software combination products in Randall’s article: https://lnkd.in/eVV5j3Jv Endeavor Venture Fund & Venture Studio #PrescriptionDigitalTherapeutics #HealthcareInnovation

In collaboration with The Dedham Group, Click Therapeutics Chief Strategy Officer, Austin Speier, and Director of Strategy, Steven L., share an overview of the FDA Prescription Drug Use-Related Software (PDURS) draft guidance, outlining the key differences from previous digital health opportunities and how this draft guidance could drive better health outcomes for patients. Learn more about this new regulatory pathway for integrating software with existing drug products here: https://lnkd.in/eYAX3vYN

Last month, the Click Therapeutics team came together for our annual Summer Bash, an opportunity to live true to our value to ‘make work fun’ and celebrate our team’s hard work and dedication! Some highlights from the week included: ◆Bowling Outing: Our team engaged in some friendly competition, but Ritesh Manchanda, our reigning ping pong champion, came out on top with a final score of 145.  ◆Paint and Sip: During happy hour, our team was led through an instructional class to paint the NYC skyline. ◆Click Fest: Showcasing our innovations to the rest of the organization, our team shared science, tech, and product demos. It was inspiring to see our team's dedication to developing innovative new treatment options. ◆Shaking Up the Boardroom: Our Women at Click Colleague Resource Group sponsored a fireside chat with two of Click’s board members, Maria Forero, MPH and Lez Cunningham who shared their insights and experiences as members of the Board with the Click team. ◆Summer Bash: We capped the week off with a rooftop party, where we celebrated as a team while raising $1,480 for American Migraine Foundation through our company raffle. At Click Therapeutics, we understand that our success is driven by our amazing team, so we take the opportunity to celebrate our colleagues seriously. Thank you to everyone who contributed to making this week a success!

Click is thrilled to be mentioned by Google CEO Sundar Pichai in the Alphabet Inc. earnings call today, showcasing how Gemini for Google Workspace helps our team collect and analyze patient sentiment and patient experience information from public forums as we build targeted digital treatments. We look forward to continually exploring new and innovative ways to leverage AI to make our digital therapeutics more engaging and patient-centric. Listen to the mention at 9 minutes and 48 seconds: https://lnkd.in/ebV6jZj7 #GoogleWorkspace #Gemini #HealthTech #PatientCentricity #DigitalTherapeutics

Click Therapeutics CEO David Benshoof Klein spoke with BiotechTV at the New York Stock Exchange about advancements in prescription digital therapeutics and the implications of the FDA’s Prescription Drug Use Related Software (PDURS) Draft Guidance on the future of treatment. Watch the full video here: https://lnkd.in/gWgGqYze #HealthTech #DigitalTherapeutics #PDURS

We're excited to share that our Data Scientist colleague, Patrick Tan, was featured in Built In’s article, "A Day in the Life of a Data Scientist". Patrick showcases the innovative data and machine learning projects he leads in addition to highlighting our team's collaborative environment to build meaningful and impactful #PrescriptionDigitalTherapeutics for patients. Check out the full article here: https://lnkd.in/eATrqeqp

At #BIO2024, Click CEO, David Benshoof Klein, joined fellow experts to discuss insights into innovative treatments and the future of mental healthcare in the panel “Challenging Biotech’s One-Track Mind in Neuropsychiatric Drug Innovation." The discussion highlighted the pressing need for innovative psychiatric treatments due to historical ineffectiveness and challenges in targeting specific brain regions. Precision medicine and novel approaches, including software-drug combinations, offer hope in filling current treatment gaps, with emphasis on affordability, scalability and personalization. David emphasized Click’s focus to address unmet needs in psychiatry and neurology through innovative treatments that target different diseases and regions of the brain. By combining software with drugs, we can achieve even more efficacious outcomes for patients. #NeuropsychiatricDrugInnovation #HealthTech #InnovationInHealthcare #PrescriptionDigitalTherapeutics

In a recent MedTech Insight article, Click CEO David Benshoof Klein and CMO Shaheen E Lakhan, MD, PhD, FAAN highlighted Click's strategic priorities, new developments in our pipeline, and the transformative potential of the FDA's latest Prescription Drug Use-Related Software (PDURS) draft guidance on #DigitalTherapeutics. Insights included: - The FDA’s “Prescription Drug Use-Related Software” draft guidance represents a pivotal opportunity for Click, as it helps clarify how combining our software as a medical device (#SaMD) with pharmacotherapy could enable pharma manufacturers to update drug labels with additional clinically meaningful benefit claims. - Leveraging digital interventions to offer personalized treatment not only improves outcomes across various health metrics like cognitive function and cardiovascular risk but also aligns with pharma's evolving demand for tailored solutions, potentially reshaping patient management and payer agreements, particularly in the GLP-1 therapy space. - Click continues to thrive by prioritizing rigorous clinical trials and demonstrating substantial clinical benefits, contrasting with competitors who faced challenges in meeting stakeholder expectations. Read more about Click's approach and our views on the future of digital therapeutics here: https://lnkd.in/epPgkPF9 #DTx #HealthInnovation #MedicalTechnology #ClinicalResearch

Lydia K., Privacy Manager, is hiring for a Privacy Specialist to join her team! If you or someone you know is interested in this position, please apply directly at the link below or reach out to our Talent Acquisition Partner, Nathan Tran. https://lnkd.in/ecFyqR7c #Hiring #PrivacySpecialist